Conatus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Conatus and buy or sell other stocks, ETFs, and their options commission-free!

About CNAT

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. 

CEO
Steven J. Mento, PhD
CEOSteven J. Mento, PhD
Employees
Employees
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2005
Founded2005
Employees
Employees

CNAT Key Statistics

Market cap
5.10K
Market cap5.10K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
137.11
Average volume137.11
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.32
52 Week high$0.32
52 Week low
$0.0011
52 Week low$0.0011

People also own

Based on the portfolios of people who own CNAT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.